FDA New Dietary Ingredient Rejections Draw “Roadmap” For Successful Notifications
This article was originally published in The Tan Sheet
Not all NDI rejections by FDA are related to safety concerns. FDA refuses to file NDIs for a variety of reasons, many of which firms can address in revised notifications that the agency will accept the second time through, industry insiders say.
You may also be interested in...
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.